SOAT1 and anemia: One of the main side effects of these drugs, linked to the intrinsic mechanism of action in JAK2-STAT pathway, seems to be the induction or the worsening of the degree of anemia in PMF patients, especially in the first 6 months of therapy; consequently the use of RBC transfusion is critical in order to avoid the tapering of drug.